Neos Therapeutics Inc. (NEOS) Reaches New 52-Week Low at $6.51
Neos Therapeutics Inc. (NASDAQ:NEOS)’s share price reached a new 52-week low during trading on Monday . The company traded as low as $6.51 and last traded at $6.57, with a volume of 58,341 shares. The stock had previously closed at $6.78.
NEOS has been the subject of a number of recent analyst reports. BMO Capital Markets started coverage on shares of Neos Therapeutics in a research note on Tuesday, June 28th. They set an “outperform” rating and a $15.00 price target for the company. Zacks Investment Research lowered shares of Neos Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, May 18th. Royal Bank Of Canada decreased their price objective on shares of Neos Therapeutics from $33.00 to $29.00 and set an “outperform” rating for the company in a report on Tuesday, May 17th. Finally, Wells Fargo & Co. reiterated a “buy” rating on shares of Neos Therapeutics in a report on Wednesday, May 18th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $21.75.
The company’s 50 day moving average is $8.27 and its 200-day moving average is $9.42. The firm’s market capitalization is $106.06 million.
Neos Therapeutics (NASDAQ:NEOS) last issued its earnings results on Thursday, August 11th. The company reported ($1.65) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.16) by $0.49. The firm had revenue of $1.49 million for the quarter, compared to analyst estimates of $1.48 million. Equities research analysts expect that Neos Therapeutics Inc. will post ($5.38) earnings per share for the current year.
In other Neos Therapeutics news, insider Juergen Martens bought 10,000 shares of Neos Therapeutics stock in a transaction dated Monday, June 13th. The stock was acquired at an average cost of $9.90 per share, for a total transaction of $99,000.00. Following the completion of the transaction, the insider now directly owns 10,000 shares of the company’s stock, valued at $99,000. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Richard I. Eisenstadt bought 3,710 shares of Neos Therapeutics stock in a transaction dated Thursday, August 25th. The stock was acquired at an average price of $6.82 per share, with a total value of $25,302.20. Following the completion of the transaction, the chief financial officer now directly owns 3,710 shares of the company’s stock, valued at $25,302.20. The disclosure for this purchase can be found here.
A hedge fund recently raised its stake in Neos Therapeutics stock. Marshall Wace LLP boosted its position in shares of Neos Therapeutics Inc. (NASDAQ:NEOS) by 11.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 96,162 shares of the company’s stock after buying an additional 9,929 shares during the period. Marshall Wace LLP owned approximately 0.60% of Neos Therapeutics worth $1,377,000 at the end of the most recent reporting period.
Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.